PROTOCOL SYNOPSISInvestigator's Agreement • August 18th, 2021
Contract Type FiledAugust 18th, 2021• Assess the response rate (≥ 5 letter gain in Best Corrected Visual Acuity [BCVA] from baseline to week 12according to ETDRS criteria) in participants with persistent central-involved DME receiving combination OPT-302 and aflibercept treatment